Impact of the interferon regulated proteins XAF1 and ZNF313 on innate immunity

干扰素调节蛋白 XAF1 和 ZNF313 对先天免疫的影响

基本信息

  • 批准号:
    7265111
  • 负责人:
  • 金额:
    $ 20.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-04-01 至 2011-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): To control viral infections the host has developed an integrated defense network that comprises both innate and adaptive immune responses. Initial responses to viral infection involve primarily the innate response and the killing of infected cells with cytotoxicity. Once the virus has invaded the cell, host-mediated responses are triggered by single stranded and doubled stranded viral RNAs that induce expression of stress cytokines including interferons (IFNs). IFNs are essential for initiating and coordinating a successful antiviral response by inducing a number of intracellular genes, the IFN-stimulated genes (ISGs), which prevent virus replication/cytolysis and stimulate the adaptive arm of the immune system. Cellular mechanisms that prevent viral replication, dissemination or persistent infections include global inhibition of protein synthesis, blockage of protein transport and induction of apoptosis. A number of cellular proteins have been implicated as mediators of virus-induced apoptosis, including two of the proteins that were the focus of our original proposal, TRAIL/Apo-2L and X-linked inhibitor of apoptosis-associated factor-1 (XAF1). IFNs also potently regulate cellular responsiveness to virus and other cellular pathogens by upregulating components of the virus detection system, including toll-like receptors, RIG-I and downstream signaling molecules. Recently, we have shown that XAF1 augments cellular sensitivity to apoptotic agents such as TRAIL, and can also enhance cellular antiviral responses. XAF1 is shown herein to impact signaling cascades initiated by TNF family ligands and dsRNA signaling cascades. This grant is designed to functionally dissect the mechanism of XAF1 activity. Emphasis will be on downstream regulators of XAF1 activity, including a newly identified protein, ZNF313, which we now show to be a XAF1-binding RING finger protein that is post-translationally regulated by IFNs. The role of this putative E3 ubiquitin ligase in regulating IFN, viral and other innate immune responses will be pursued as outlined in the following aims. We will also pursue recent data linking XAF1 to other signaling molecules that regulate ubiquitin ligation, including TRAF2 and RIP2, and demonstrate that TRIP6, another XAF1 binding partner, may represent a novel ubiquitination regulator in the TNF/dsRNA pathway.
描述(申请人提供):为了控制病毒感染,宿主发展了一个包括先天免疫反应和获得性免疫反应的综合防御网络。对病毒感染的初始反应主要包括先天反应和对具有细胞毒性的受感染细胞的杀伤。一旦病毒入侵细胞,宿主介导的反应由单链和双链病毒RNA触发,诱导包括干扰素(IFN)在内的应激细胞因子的表达。干扰素对启动和协调成功的抗病毒反应至关重要,它通过诱导一些细胞内基因,即干扰素刺激基因(ISGs),防止病毒复制/细胞溶解,并刺激免疫系统的适应性臂。防止病毒复制、传播或持续感染的细胞机制包括全球抑制蛋白质合成、阻断蛋白质运输和诱导细胞凋亡。许多细胞蛋白被认为是病毒诱导的细胞凋亡的媒介,包括我们最初提出的两个蛋白,TRAIL/Apo-2L和X-连锁的凋亡相关因子抑制因子-1(XAF1)。IFN还通过上调病毒检测系统的组件,包括Toll样受体、RIG-I和下游信号分子,有效地调节细胞对病毒和其他细胞病原体的反应。最近,我们发现XAF1增强了细胞对TRAIL等凋亡剂的敏感性,并能增强细胞的抗病毒反应。XAF1在这里显示了影响由肿瘤坏死因子家族配体启动的信号级联和dsRNA信号级联。这项授权旨在从功能上剖析XAF1活动的机制。重点将放在XAF1活性的下游调节因子上,包括一种新发现的蛋白质ZNF313,我们现在证明它是一种XAF1结合的环指蛋白,受IFN翻译后调控。这种假定的E3泛素连接酶在调节干扰素、病毒和其他先天免疫反应中的作用将在以下目标中进行研究。我们还将继续追踪最近将XAF1与调节泛素连接的其他信号分子(包括TRAF2和RIP2)联系起来的数据,并证明另一个XAF1结合伙伴TRIP6可能代表着肿瘤坏死因子/dsRNA途径中的一种新的泛素化调节因子。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Douglas W Leaman其他文献

Douglas W Leaman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Douglas W Leaman', 18)}}的其他基金

Prevention of adenovirus pathogenesis through downregulation of the apical adenovirus receptor
通过下调顶端腺病毒受体预防腺病毒发病机制
  • 批准号:
    9750122
  • 财政年份:
    2017
  • 资助金额:
    $ 20.97万
  • 项目类别:
Role of ISG12 in cellular innate immune responses
ISG12 在细胞先天免疫反应中的作用
  • 批准号:
    7849979
  • 财政年份:
    2009
  • 资助金额:
    $ 20.97万
  • 项目类别:
2-5A Antisense Targeting of Telomerase RNA
2-5A 端粒酶 RNA 的反义靶向
  • 批准号:
    6405499
  • 财政年份:
    2003
  • 资助金额:
    $ 20.97万
  • 项目类别:
Molecular Mediators of Interferon induced Apoptosis
干扰素诱导细胞凋亡的分子介质
  • 批准号:
    6875026
  • 财政年份:
    2001
  • 资助金额:
    $ 20.97万
  • 项目类别:
Molecular Mediators of Interferon induced Apoptosis
干扰素诱导细胞凋亡的分子介质
  • 批准号:
    6323066
  • 财政年份:
    2001
  • 资助金额:
    $ 20.97万
  • 项目类别:
Impact of the interferon regulated proteins XAF1 and ZNF313 on innate immunity
干扰素调节蛋白 XAF1 和 ZNF313 对先天免疫的影响
  • 批准号:
    7908857
  • 财政年份:
    2001
  • 资助金额:
    $ 20.97万
  • 项目类别:
Molecular Mediators of Interferon induced Apoptosis
干扰素诱导细胞凋亡的分子介质
  • 批准号:
    6717750
  • 财政年份:
    2001
  • 资助金额:
    $ 20.97万
  • 项目类别:
Impact of the interferon regulated proteins XAF1 and ZNF313 on innate immunity
干扰素调节蛋白 XAF1 和 ZNF313 对先天免疫的影响
  • 批准号:
    7476515
  • 财政年份:
    2001
  • 资助金额:
    $ 20.97万
  • 项目类别:
Impact of the interferon regulated proteins XAF1 and ZNF313 on innate immunity
干扰素调节蛋白 XAF1 和 ZNF313 对先天免疫的影响
  • 批准号:
    7145018
  • 财政年份:
    2001
  • 资助金额:
    $ 20.97万
  • 项目类别:
Molecular Mediators of Interferon induced Apoptosis
干扰素诱导细胞凋亡的分子介质
  • 批准号:
    6634025
  • 财政年份:
    2001
  • 资助金额:
    $ 20.97万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 20.97万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 20.97万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 20.97万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 20.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 20.97万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 20.97万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 20.97万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 20.97万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 20.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 20.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了